SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology, hematology, and infectious & inflammatory diseases, announced today ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Loqtorzi (toripalimab) showed significant improvement in progression-free survival for acral melanoma compared to standard chemotherapy in a phase 3 trial. Acral melanoma, a rare and aggressive ...

Registrational Phase 3 study for advanced melanoma immunotherapy delivered with PharmaJet's IM Needle-free System planned for ...

Lymph node dissection, the standard surgical treatment for melanoma, does not increase patient survival rates, according to a study published in The New England Journal of Medicine. Lymph node ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Mitotic rate ≥1/mm² and residual tumor presence are linked to higher relapse risk in cutaneous melanoma patients post-excision. Lymphovascular invasion significantly correlates with worse relapse-free ...

Iovance Biotherapeutics announced positive five-year results from its Phase 2 C-144-01 clinical trial for Amtagvi® (lifileucel), a T cell therapy for advanced melanoma patients who previously received ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

Regional anesthesia can improve survival rates in patients with malignant melanoma, the deadliest form of skin cancer, according to a study presented at this year’s American Society of ...

The study assessed the overall diagnostic accuracy of the Merlin CP-GEP Test for predicting sentinel node metastases and recurrence riskThe Merlin CP-GEP Test demonstrated strong predictive ...